267 related articles for article (PubMed ID: 37123954)
21. Effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat on renal anemia in non-dialysis-dependent chronic kidney disease: a systematic review and meta-analysis.
Jia L; Dong X; Yang J; Jia R; Zhang H
Ann Transl Med; 2019 Dec; 7(23):720. PubMed ID: 32042736
[TBL] [Abstract][Full Text] [Related]
22. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
[TBL] [Abstract][Full Text] [Related]
23. Roxadustat alleviates the inflammatory status in patients receiving maintenance hemodialysis with erythropoiesis-stimulating agent resistance by increasing the short-chain fatty acids producing gut bacteria.
Zhao XN; Liu SX; Wang ZZ; Zhang S; You LL
Eur J Med Res; 2023 Jul; 28(1):230. PubMed ID: 37430374
[TBL] [Abstract][Full Text] [Related]
24. An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease.
Kurata Y; Tanaka T; Nangaku M
Expert Opin Pharmacother; 2022 Jan; 23(1):19-28. PubMed ID: 34686069
[TBL] [Abstract][Full Text] [Related]
25. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
Weir MR
Am J Nephrol; 2021; 52(6):450-466. PubMed ID: 34280923
[TBL] [Abstract][Full Text] [Related]
26. Stabilizing Hypoxia-Inducible Factor to Manage Anemia in Chronic Kidney Disease: From Basic Theory to Clinical Study.
Wang Y; Yu X
Kidney Dis (Basel); 2024 Apr; 10(2):132-142. PubMed ID: 38659701
[TBL] [Abstract][Full Text] [Related]
27. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease.
Haase VH
Kidney Int Suppl (2011); 2021 Apr; 11(1):8-25. PubMed ID: 33777492
[TBL] [Abstract][Full Text] [Related]
28. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in heart failure patients: A protocol for systematic review and meta-analysis.
Fukuta H; Hagiwara H; Kamiya T
PLoS One; 2022; 17(9):e0275311. PubMed ID: 36170343
[TBL] [Abstract][Full Text] [Related]
29. The Efficacy and Safety of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis.
Wang L; Yin H; Yang L; Zhang F; Wang S; Liao D
Front Pharmacol; 2022; 13():779694. PubMed ID: 35559232
[No Abstract] [Full Text] [Related]
30. Efficacy and Safety of Roxadustat in Patients with Chronic Kidney Disease: An Updated Meta-Analysis of Randomized Controlled Trials including 6,518 Patients.
Lei J; Li H; Wang S
Biomed Res Int; 2022; 2022():2413176. PubMed ID: 36420092
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitor treatment for anemia in chronic kidney disease: an umbrella review of meta-analyses.
Ren S; Yao X; Li Y; Zhang Y; Tong C; Feng Y
Front Pharmacol; 2023; 14():1296702. PubMed ID: 38099145
[TBL] [Abstract][Full Text] [Related]
32. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis.
Zheng L; Tian J; Liu D; Zhao Y; Fang X; Zhang Y; Liu Y
Br J Clin Pharmacol; 2022 Mar; 88(3):919-932. PubMed ID: 34428860
[TBL] [Abstract][Full Text] [Related]
34. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
Kurata Y; Tanaka T; Nangaku M
Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
[TBL] [Abstract][Full Text] [Related]
35. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular safety of current and emerging drugs to treat anaemia in chronic kidney disease: a safety review.
Locatelli F; Paoletti E; Del Vecchio L
Expert Opin Drug Saf; 2023; 22(12):1179-1191. PubMed ID: 38111209
[TBL] [Abstract][Full Text] [Related]
37. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Patients with Renal Anemia: A Meta-Analysis of Randomized Trials.
Wen T; Zhang X; Wang Z; Zhou R
Nephron; 2020; 144(11):572-582. PubMed ID: 32866960
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis.
Zhang S; Guo J; Xie S; Chen J; Yu S; Yu Y
Int Urol Nephrol; 2021 Jun; 53(6):1139-1147. PubMed ID: 33026571
[TBL] [Abstract][Full Text] [Related]
39. The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis.
Zhou Q; Mao M; Li J; Deng F
Ren Fail; 2023 Dec; 45(1):2195011. PubMed ID: 37489561
[TBL] [Abstract][Full Text] [Related]
40. Effect of roxadustat on iron metabolism in patients with peritoneal dialysis: a real-world 24-week study.
Zhang X; Jia R; Zheng Z; Jiang L; Xu Y; Raj A; Sun D
Eur J Med Res; 2023 Nov; 28(1):489. PubMed ID: 37936193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
